Abstract
Anti-TNF therapy has revolutionized the treatment of inflammatory bowel diseases, including both Crohn's disease and ulcerative colitis. However, a significant proportion of patients does not respond to anti-TNF agents or lose response over time. Recently, therapeutic drug monitoring has gained a major role in identifying the mechanism and management of loss of response. The aim of this review article is to summarize the predictors of efficacy and outcomes, the different mechanisms of anti-TNF/biological failure in Crohn's disease and identify strategies to optimize biological treatment.
| Original language | English |
|---|---|
| Pages (from-to) | 37-45 |
| Number of pages | 9 |
| Journal | Expert Review of Gastroenterology and Hepatology |
| Volume | 10 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 1 Jan 2016 |
Keywords
- adalimumab
- Crohn's disease
- infliximab
- Therapeutic drug level monitoring
- Ulcerative colitis
Fingerprint
Dive into the research topics of 'Optimizing biological therapy in Crohn's disease'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver